Canadian Branded Drug Makers Miss R&D Target

Law360, New York (October 26, 2004, 12:00 AM EDT) -- Canadian branded drug makers are spending less on research and development than they pledged to under a deal to get passage of stricter patent laws more than a decade ago, a new survey has found.

In 1987 and 1993, Prime Minister Brian Mulroney's conservative government agreed to overhaul Canada’s drug patent laws in favor of the branded drug industry by ending the process of compulsory licensing that had allowed generic drug makers to produce lower-cost versions of a patented medicines in return for a small royalty....
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.